TY - JOUR
T1 - CD5-negative Mantle Cell Lymphoma
T2 - Clinicopathologic Correlations and Outcome in 58 Patients
AU - Miao, Yuan
AU - Lin, Pei
AU - Saksena, Annapurna
AU - Xu, Jie
AU - Wang, Michael
AU - Romaguera, Jorge
AU - Yin, C. Cameron
AU - Medeiros, L. Jeffrey
AU - Li, Shaoying
N1 - Publisher Copyright:
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Mantle cell lymphoma (MCL) represents 4% to 9% of all non-Hodgkin lymphomas and is characterized by CD5 and cyclin D1 expression and t(11;14)(q13;q32). However, about 5% of MCL lack CD5 expression and is poorly characterized. Here, we present 58 patients with CD5 negative (CD5-) MCL and compared them with a group of 212 typical CD5 positive (CD5+) MCL cases. There were 39 men and 19 women with a median age of 66 years (range, 36 to 88). Compared with CD5 positive (CD5+) MCL patients, patients with CD5- MCL showed a lower male-To-female ratio (P=0.006) and a higher frequency of "bone marrow non-nodal" presentation (P=0.01). All other clinicopathologic features, including the frequency of SOX11 expression, were similar between the 2 groups. Treated with similar regimens, patients with CD5- MCL showed a significantly longer progression-free survival (PFS) (P=0.01) and a tendency for longer overall survival (OS; P=0.078) than CD5 positive (CD5+) MCL patients. Univariate analysis showed of the well-known poor prognostic factors, only Mantle Cell Lymphoma International Prognostic Index was an inferior prognostic factor and blastoid/pleomorphic morphology and high Ki67 were not associated with prognosis in CD5- MCL patients. Multivariate Cox regression analysis showed CD5 expression was an independent prognostic factor for PFS (P=0.031) but not OS in MCL patients. In conclusion, the results suggest that patients with CD5- MCL have a more favorable prognosis than CD5+ MCL patients, although the clinicopathologic features of both groups are largely similar. CD5- MCL may represent a distinct variant of MCL and needs to be included in the differential diagnosis of CD5- small B-cell lymphomas.
AB - Mantle cell lymphoma (MCL) represents 4% to 9% of all non-Hodgkin lymphomas and is characterized by CD5 and cyclin D1 expression and t(11;14)(q13;q32). However, about 5% of MCL lack CD5 expression and is poorly characterized. Here, we present 58 patients with CD5 negative (CD5-) MCL and compared them with a group of 212 typical CD5 positive (CD5+) MCL cases. There were 39 men and 19 women with a median age of 66 years (range, 36 to 88). Compared with CD5 positive (CD5+) MCL patients, patients with CD5- MCL showed a lower male-To-female ratio (P=0.006) and a higher frequency of "bone marrow non-nodal" presentation (P=0.01). All other clinicopathologic features, including the frequency of SOX11 expression, were similar between the 2 groups. Treated with similar regimens, patients with CD5- MCL showed a significantly longer progression-free survival (PFS) (P=0.01) and a tendency for longer overall survival (OS; P=0.078) than CD5 positive (CD5+) MCL patients. Univariate analysis showed of the well-known poor prognostic factors, only Mantle Cell Lymphoma International Prognostic Index was an inferior prognostic factor and blastoid/pleomorphic morphology and high Ki67 were not associated with prognosis in CD5- MCL patients. Multivariate Cox regression analysis showed CD5 expression was an independent prognostic factor for PFS (P=0.031) but not OS in MCL patients. In conclusion, the results suggest that patients with CD5- MCL have a more favorable prognosis than CD5+ MCL patients, although the clinicopathologic features of both groups are largely similar. CD5- MCL may represent a distinct variant of MCL and needs to be included in the differential diagnosis of CD5- small B-cell lymphomas.
KW - CD5
KW - mantle cell lymphoma
KW - overall survival
KW - prognosis
KW - progression-free survival
UR - http://www.scopus.com/inward/record.url?scp=85065323149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065323149&partnerID=8YFLogxK
U2 - 10.1097/PAS.0000000000001278
DO - 10.1097/PAS.0000000000001278
M3 - Article
C2 - 31045891
AN - SCOPUS:85065323149
SN - 0147-5185
VL - 43
SP - 1052
EP - 1060
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 8
ER -